Last reviewed · How we verify
Anti-aromatase inhibitor
Anti-aromatase inhibitor is a Aromatase inhibitor Small molecule drug developed by UNICANCER. It is currently in Phase 2 development for Breast cancer.
Inhibits the enzyme aromatase
Inhibits the enzyme aromatase Used for Breast cancer.
At a glance
| Generic name | Anti-aromatase inhibitor |
|---|---|
| Sponsor | UNICANCER |
| Drug class | Aromatase inhibitor |
| Target | Aromatase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Aromatase is an enzyme involved in the biosynthesis of estrogens from androgen precursors. Inhibiting this enzyme reduces estrogen levels, which can slow the growth of hormone receptor-positive breast cancer cells.
Approved indications
- Breast cancer
Common side effects
- Hot flashes
- Vaginal dryness
- Musculoskeletal pain
Key clinical trials
- Effects of Activity on Diabetes Risk Among Breast Cancer Survivors on Endocrine Therapy (ABIDE)
- Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer
- A Study of Single Dose of BL0175 in Postmenopausal Women (PHASE1)
- Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia (NA)
- CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer (PHASE3)
- AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) (PHASE1)
- Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors (NA)
- Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-aromatase inhibitor CI brief — competitive landscape report
- Anti-aromatase inhibitor updates RSS · CI watch RSS
- UNICANCER portfolio CI
Frequently asked questions about Anti-aromatase inhibitor
What is Anti-aromatase inhibitor?
How does Anti-aromatase inhibitor work?
What is Anti-aromatase inhibitor used for?
Who makes Anti-aromatase inhibitor?
What drug class is Anti-aromatase inhibitor in?
What development phase is Anti-aromatase inhibitor in?
What are the side effects of Anti-aromatase inhibitor?
What does Anti-aromatase inhibitor target?
Related
- Drug class: All Aromatase inhibitor drugs
- Target: All drugs targeting Aromatase
- Manufacturer: UNICANCER — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer
- Compare: Anti-aromatase inhibitor vs similar drugs
- Pricing: Anti-aromatase inhibitor cost, discount & access